当前位置： SCI文献检索 > CURRENT CANCER DRUG TARGETS期刊下所有文献 > Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.

Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.

Abstract：

:Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of our systemic analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to inhibit Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and JAK2/signal transducer and activator of transcription 5 (STAT5) signaling and thus are attractive scaffolds for anticancer drug design. To identify the potential mechanisms of action of this class of compounds, direct interactions of the selected CABA analogs with JAK2 kinase were examined. Inhibition of JAK2 enzymatic activity was assessed, and molecular modeling studies of selected compounds-(E)-2-cyano-N-[(S)-1-phenylethyl]-3-(pyridin-2-yl)acrylamide (WP1065), (E)-2-cyano-N-[(S)-1-phenylbutyl]- 3-(3-bromopyridin-2-yl)acrylamide (WP1130), and (E)-2-cyano-N-[(S)-1,4-diphenylbutyl]-3-(3-bromopyridin-2-yl)acrylamide (WP1702)-in the JAK2 kinase domain were used to support interpretation of the experimental data. Our results indicated that the tested CABA analogs are nonclassical inhibitors of activated (phosphorylated) JAK2, although markedly weaker than clinically tested ATP-competitive JAK2 inhibitors. Relatively small structural changes in the studied compounds affected interactions with JAK2, and their mode of action ranged from allosteric-noncompetitive to bisubstratecompetitive. These results demonstrated that direct inhibition of JAK2 enzymatic activity by the WP1065 (half-maximal inhibitory concentration [IC₅₀] = 14.8 µM), WP1130 (IC₅₀ = 3.8 µM), and WP1702 (IC₅₀ = 2.9 µM) potentially contributes, albeit minimally, to suppression of the JAK2/STAT signaling pathways in cancer cells and that additional specific structural modifications may amplify JAK2-inhibitory effects.

journal_name

Curr Cancer Drug Targets

journal_title

Current cancer drug targets

authors

Mielecki M,Milner-Krawczyk M,Grzelak K,Mielecki D,Krzysko KA,Lesyng B,Priebe W

doi

10.2174/1568009614666140821122718

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

638-51

issue

7

eissn

1568-0096

issn

1873-5576

pii

CCDT-EPUB-61870

journal_volume

14

pub_type

杂志文章

相关文献

CURRENT CANCER DRUG TARGETS文献大全
  • The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.

    abstract：BACKGROUND:The solute carrier family 7 (SLC7) can be categorically divided into two subfamilies, the L-type amino acid transporters (LATs) including SLC7A5-13, and SLC7A15, and the cationic amino acid transporters (CATs) including SLC7A1-4 and SLC7A14. Members of the CAT family transport predominantly cationic amino ac...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009619666190802135714

    authors： Lu X

    更新日期：2019-01-01 00:00:00

  • Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

    abstract：:The treatment of advanced non � small cell lung cancer (NSCLC) increasingly involves the use of molecularly targeted therapy with activity against either the tumor directly, or indirectly, through activity against host-derived mechanisms of tumor support such as angiogenesis. The most well studied signaling pathway as...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/156800912799095144

    authors： Kono SA,Heasley LE,Doebele RC,Camidge DR

    更新日期：2012-02-01 00:00:00

  • Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.

    abstract：:Malignant brain tumors including primary brain tumors (e.g., glioblastoma multiforme) and metastases, are aggressive and lethal entities for the majority of affected patients. Current standard treatments involving combinations of surgery, radiotherapy and systemic chemotherapy offer only modest improvements in surviva...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009615666150616123548

    authors： Drapeau A,Fortin D

    更新日期：2015-01-01 00:00:00

  • CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.

    abstract：BACKGROUND:Approximately one third of Diffuse Large B cell Lymphomas (DLBCL) are refractory or relapse. Novel therapeutic approaches under scrutiny include inhibitors of B-cell receptor (BCR) signaling. Protein kinase CK2 propels survival, proliferation and stress response in solid and hematologic malignancies and prom...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009617666170427110450

    authors： Mandato E,Nunes SC,Zaffino F,Casellato A,Macaccaro P,Tubi LQ,Visentin A,Trentin L,Semenzato G,Piazza F

    更新日期：2018-01-01 00:00:00

  • Nanoradiopharmaceuticals for Bone Cancer Metastasis Imaging.

    abstract：:Drug delivery systems are under intense investigation all around the world, especially in oncology research. Indeed, in some cases, like bone metastasis, nanodrugs may represent the last and best choice for both treatment and imaging of early cancer foci. Nuclear medicine has been using MDP labelled with 99mTc as radi...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009615666150407125020

    authors： Coelho BF,de Souza Albernaz M,Iscaife A,Moreira Leite KR,de Souza Junqueira M,Bernardes ES,da Silva EO,Santos-Oliveira R

    更新日期：2015-01-01 00:00:00

  • Apoptosis suppression by candidate oncogene PLAC8 is reversed in other cell types.

    abstract：:Targets for cancer therapy are conventionally selected by identification of molecules acting downstream of established tumour suppressors and oncoproteins, such as p53, c-Myc and Ras. However, the forward genetics approach provides an alternative, conceptually distinct, strategy for identifying target molecules de nov...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：

    authors： Mourtada-Maarabouni M,Watson D,Munir M,Farzaneh F,Williams GT

    更新日期：2013-01-01 00:00:00

  • Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

    abstract：:Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membran...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009611313020008

    authors： Grunt TW,Mariani GL

    更新日期：2013-02-01 00:00:00

  • Effects of Iron Chelation in Osteosarcoma.

    abstract：BACKGROUND:Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic properties in many tumors. Deferasirox is the most used iron chelator co...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009620666201230090531

    authors： Argenziano M,Di Paola A,Tortora C,Di Pinto D,Pota E,Di Martino M,Perrotta S,Rossi F,Punzo F

    更新日期：2020-12-29 00:00:00

  • Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.

    abstract：:One of the challenges of cancer therapeutics is to discover targets unique to the tumor cell population. Constitutively activated tyrosine kinases play a role in the malignant phenotype in a number of different cancers. While the kinases may be present in the normal cell, the cancer cell is often dependent upon the ac...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/156800906779010209

    authors： Ritchie E,Nichols G

    更新日期：2006-12-01 00:00:00

  • Black currant anthocyanins abrogate oxidative stress through Nrf2- mediated antioxidant mechanisms in a rat model of hepatocellular carcinoma.

    abstract：:Hepatocellular carcinoma (HCC), considered to be one of the most lethal cancers with almost > 1 million deaths reported annually worldwide, remains a devastating disease with no known effective cure. Hence, chemopreventive strategies come into play, offering an effective and safe mode of treatment, ideal to ward off p...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800912803987968

    authors： Thoppil RJ,Bhatia D,Barnes KF,Haznagy-Radnai E,Hohmann J,Darvesh AS,Bishayee A

    更新日期：2012-11-01 00:00:00

  • Cyclophilin A as a target of Cisplatin chemosensitizers.

    abstract：:Platinum-based chemotherapeutics are the mainstay of treatment of a range of tumors achieving high response rates but limited in the course of disease by appearance of drug resistance. Tumor cells respond with reduced uptake and increased intracellular inactivation of the drugs, as well as increased DNA repair and gen...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/15680096113136660109

    authors： Hamilton G

    更新日期：2014-01-01 00:00:00

  • Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.

    abstract：:CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800910793605839

    authors： D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

    更新日期：2010-11-01 00:00:00

  • Tumor-targeted inhibition by a novel strategy - mimoretrovirus expressing siRNA targeting the Pokemon gene.

    abstract：:Pokemon gene has crucial but versatile functions in cell differentiation, proliferation and tumorigenesis. It is a master regulator of the ARF-HDM2-p53 and Rb-E2F pathways. The facts that the expression of Pokemon is essential for tumor formation and many kinds of tumors over-express the Pokemon gene make it an attrac...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800910793357907

    authors： Tian Z,Wang H,Jia Z,Shi J,Tang J,Mao L,Liu H,Deng Y,He Y,Ruan Z,Li J,Wu Y,Ni B

    更新日期：2010-12-01 00:00:00

  • Targeting NUPR1 for Cancer Treatment: A Risky Endeavor.

    abstract：:NUPR1 is a transcription factor that has attracted great attention because of its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 ...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009620666200703152523

    authors： Mansour SMA,Ali SA,Nofal S,Soror SH

    更新日期：2020-01-01 00:00:00

  • Molecular targets of the oncogenic transcription factor jun.

    abstract：:The Jun oncoprotein is a major component of the transcription factor complex AP-1, which regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Constitutive activation of endogenous AP-1 is required for tumor formation in avian and mammalian cell transformation syst...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009033333781

    authors： Hartl M,Bader AG,Bister K

    更新日期：2003-02-01 00:00:00

  • A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

    abstract：:Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800911795656001

    authors： Cai T,Li X,Ding J,Luo W,Li J,Huang C

    更新日期：2011-06-01 00:00:00

  • Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.

    abstract：:Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/15680096113139990038

    authors： Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

    更新日期：2013-07-01 00:00:00

  • Targeted histone deacetylase inhibition for cancer therapy.

    abstract：:The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009043481560

    authors： Vigushin DM,Coombes RC

    更新日期：2004-03-01 00:00:00

  • Understanding FOXO, new views on old transcription factors.

    abstract：:FOXO proteins are evolutionarily conserved transcription factors implicated in several fundamental cellular processes, functioning as end-point for transcriptional programs involved in apoptosis, stress response and longevity. Abrogation of FOXO function is very frequent in human cancer, therefore the mechanisms of re...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800910791054158

    authors： Zanella F,Link W,Carnero A

    更新日期：2010-03-01 00:00:00

  • Tumor-Induced Metabolism and T Cells Located in Tumor Environment.

    abstract：:Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cell...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009620666200720010647

    authors： Iranparast S,Tayebi S,Ahmadpour F,Yousefi B

    更新日期：2020-01-01 00:00:00

  • Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

    abstract：:Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, en...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800912801784839

    authors： Matsuhashi A,Ohno T,Kimura M,Hara A,Saio M,Nagano A,Kawai G,Saitou M,Takigami I,Yamada K,Okano Y,Shimizu K

    更新日期：2012-07-01 00:00:00

  • Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors.

    abstract：BACKGROUND:Intestinal β-glucuronidase enzyme has a significant importance in colorectal carcinogenesis. Specific inhibition of the enzyme helps prevent immune reactivation of the glucuronide- carcinogens, thus protecting the intestine from ROS (Reactive Oxidative Species) mediatedcarcinogenesis. OBJECTIVES:Advancement...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009619666190320102238

    authors： Yousuf M

    更新日期：2019-01-01 00:00:00

  • TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines.

    abstract：:Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009614666141028094612

    authors： Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

    更新日期：2015-01-01 00:00:00

  • Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy.

    abstract：:Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcin...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009618666171129223533

    authors： Wu J,Di D,Zhao C,Liu Y,Chen H,Gong Y,Zhao X,Chen H

    更新日期：2018-01-01 00:00:00

  • Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies.

    abstract：:The evolution of genomic research enabled the genetic and molecular profiling of breast cancer and revealed the profound complexity and heterogeneity of this disease. Subtypes of breast cancer characterized by mutations and/or amplifications of some proto-oncogenes are associated with an increased rate of recurrence a...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/1568009616666160603123014

    authors： Guerram M,Hamdi AM,Zhang LY,Jiang Z

    更新日期：2017-01-01 00:00:00

  • HER-2 signaling and inhibition in breast cancer.

    abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/156800909788166484

    authors： Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

    更新日期：2009-05-01 00:00:00

  • Role of the RAS in pancreatic cancer.

    abstract：:Angiotensin II (Ang II), a main effector peptide of the renin-angiotensin system (RAS), mediates a hormonal action in the maintenance of blood pressure and electrolyte levels, and thus fluid homeostasis. Ang II also mediates paracrine, autocrine and/or intracrine actions in the control of various specific functions of...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章,评审

    doi：10.2174/156800911795538110

    authors： Lau ST,Leung PS

    更新日期：2011-05-01 00:00:00

  • Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

    abstract：:Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/156800909789057024

    authors： Gleixner KV,Mayerhofer M,Vales A,Gruze A,Hörmann G,Cerny-Reiterer S,Lackner E,Hadzijusufovic E,Herrmann H,Iyer AK,Krauth MT,Pickl WF,Marian B,Panzer-Grümayer R,Sillaber C,Maeda H,Zielinski C,Valent P

    更新日期：2009-08-01 00:00:00

  • Gene Therapy and Photothermal Therapy of Layer-by-Layer Assembled AuNCs /PEI/miRNA/ HA Nanocomplexes.

    abstract：BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009618666181016144855

    authors： Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

    更新日期：2019-01-01 00:00:00

  • Selective Antitumor Effect of Shikonin Derived DMAKO-20 on Melanoma through CYP1B1.

    abstract：BACKGROUND:CYP1B1 is recognized as a valuable target for chemotherapy. It catalyzes the bioactivation of naphthoquinone oximes within certain cancer cell lines. However, the expression level of CYP1B1 in melanoma and the functional role regulating the activity of DMAKO-20 as a representative naphthoquinone oxime agains...

    journal_title：Current cancer drug targets

    pub_type： 杂志文章

    doi：10.2174/1568009620666201116112937

    authors： Cui J,Zhou X,Huang J,Cui J,Chen J

    更新日期：2020-11-15 00:00:00